The honest answer to the question of which NMN dose is recommended is that no authority recommends one. What exists is a set of doses used in trials and one safety opinion from EFSA. This guide lays them out as a ladder, rung by rung. It says what each rung is and is not. It is not a dosing guide.
Why there is no recommended dose
The Verbraucherzentrale states that NMN is a novel food and may not be used in food supplements or other foods in the EU. EFSA gave a positive safety opinion on one applicant's NMN in May 2026, which is a step towards approval and not an approval. The sources checked show no authorisation yet. The position can change. Without an authorisation there is no entry on the Union list with conditions of use. That means no official recommended or maximum daily amount. A product page that names a daily dose is the seller's own suggestion. For comparison, the Verbraucherzentrale notes that for NAD and NADH the EU sets no quantity limit and leaves safe daily doses to the manufacturer.
Rung 1: 250 mg a day, the most common trial dose
A 2025 meta analysis in Current Diabetes Reports pooled eight randomised trials with 342 participants. Doses ranged from 250 to 2000 mg a day. The most common was 250 mg a day, used in four of the eight studies. The best known single trial, published in Science in 2021, gave 13 prediabetic postmenopausal women 250 mg a day for 10 weeks, against 12 on placebo. Insulin worked better in their muscle, while blood glucose, lipids and liver fat did not change. This rung shows what was tested. It does not show what is needed.
Rung 2: 300 mg a day, the EFSA figure
According to a trade report, EFSA's May 2026 opinion on one applicant's NMN considered a daily intake of 300 mg safe for the general population, excluding pregnant and breastfeeding women. That is a safety assessment for a specific product and applicant. It is not an authorisation. It is not a recommendation to take that amount. The report also notes that a 90 day toxicity study in the application showed changes in blood counts, blood chemistry and organ weights, which an industry source described as unimportant and unrelated to treatment. The same report mentions a 60 day trial at 300 mg in which the improvement in six minute walk distance was not significant compared with placebo.
Rung 3: 600 to 900 mg a day
A 2024 review in Cureus by Wen and colleagues covered ten placebo controlled trials with 437 participants and doses from 150 to 1200 mg a day. In one of the trials, six minute walk distance was longer in the 600 and 900 mg groups than with placebo. The review judged the overall gains in strength and aerobic performance to be non significant and the evidence too limited for firm conclusions. A dose dependent effect was suggested, not shown.
Rung 4: 1000 mg and above
The Chen meta analysis notes that side effects tended to be more frequent at 1000 mg a day or more. It also raises theoretical worries, including how the body handles extra nicotinamide, for which an upper limit of 900 mg a day is mentioned. The Wen review reported adverse events in 8.2 percent of participants, none severe and none judged related to NMN, with rates no different from placebo. These are short trials of up to 12 weeks. Nothing is known about years of use.
Rung 5: 2000 mg for 14 days
The highest dose in the meta analysis was 2000 mg a day for 14 days. A fortnight at a very high dose says almost nothing about long term safety or benefit. It shows the top of what has been tried in a trial. It says nothing more.
What a self reported dose is worth
Some well known longevity figures talk about their own daily NMN intake. A 2026 retailer article reports that David Sinclair has long said he takes about 1 g each morning. It notes that the article does not verify the dose against any study. A personal routine is not evidence and not a recommendation.
What the ladder does not show
It does not show a dose that works. The meta analysis found no significant benefit for blood sugar or lipids at any dose in mostly healthy adults. The Verbraucherzentrale says there is no scientific evidence that NMN makes people healthier or extends life. No trial found a dose that slows ageing. The ladder only tells readers what was given to volunteers under supervision.
Who must be especially careful
EFSA's opinion excluded pregnant and breastfeeding women. The reviews note that people with cancer and people on many medications were barely studied. The Verbraucherzentrale, citing the Krebsinformationsdienst, says that NAD and related substances could in theory also support tumour growth. The Apotheken Umschau quotes Prof. Andrea Britta Maier saying that NMN should be used only under medical supervision. The AOK advises avoiding NMN products. Any decision about an amount belongs with a doctor.
Why men should care
Men who optimise like to find the number. With NMN the number is a trial setting and not a prescription. A dose that was safe in a ten week study of volunteers says little about a daily habit that runs for years.
Questions men ask
Which NMN dose is officially recommended?
None. NMN has no authorisation in the EU in the sources checked, so there is no official recommended or maximum amount.
What doses were used in trials?
A 2025 meta analysis covered 250 to 2000 mg a day, with 250 mg most common. A 2024 review covered 150 to 1200 mg a day.
What did EFSA say?
A May 2026 opinion on one applicant's NMN considered 300 mg a day safe for the general population excluding pregnant and breastfeeding women. It is not an authorisation.
Do higher doses work better?
No clear evidence. Side effects tended to be more frequent at 1000 mg a day or more.
Who should decide on an amount?
A doctor.
No dose tips from us
At LongevityLife we do not hand out dose tips. Anyone who sells a number to a stranger is guessing. We would rather say so. A brand that explains what the studies used and then points to a doctor could be the best one to ask. Questions are welcome at mylongevitylife.com.
The bottom line
There is no recommended NMN dose. There are trial doses, one EFSA safety opinion for one product and a lot of self reported routines. None of them is advice. A doctor should decide on anything beyond that. The legal position in the EU is unresolved.
This article is for information only and does not replace medical advice.
